Engflag

Hawksone

Quick links to important sections

Hawksone

Hawksone_DA

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hawksone

Hawksone is a single-agent pharmaceutical preparation containing the active ingredient Piroxicam, a well-established substance classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is primarily used to provide relief from the symptoms of inflammation.

Property Description
Active ingredient Piroxicam
Form Capsules, tablets, gel, injectable solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Origin Synthetic small molecule
General purpose Relief of pain, stiffness, and swelling

Hawksone: Definition and Pharmacological Classification

Hawksone is a synthetic medication whose core component is Piroxicam. It belongs to the oxicam class of drugs and is structurally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification confirms its therapeutic role as an anti-inflammatory agent that operates without the use of corticosteroids.

The general function of Piroxicam is achieved by inhibiting the process that creates pro-inflammatory hormones, such as prostaglandins, throughout the body’s tissues. This mechanism gives the substance its characteristic three-way action as an anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) agent. The key differentiating characteristic of Piroxicam is its clinically recognized long elimination half-life, a property that supports its sustained therapeutic effect compared to many other shorter-acting NSAIDs.

Composition and Available Pharmaceutical Forms

The composition is built around Piroxicam as the single active ingredient. The medication is often categorized as a prescription-only (Rx-only) drug, typically used by adults for chronic symptom management. The drug is available in several high-level dosage forms, including capsules and tablets for oral use, a gel for topical application, and an injectable solution intended for parenteral routes of administration. These diverse formulations allow the drug’s core action—the reduction of pro-inflammatory mediators—to be delivered systemically or locally.

General Purpose and Therapeutic Benefit

The overall purpose of Hawksone is to manage discomfort by providing significant symptomatic relief from inflammation. Piroxicam’s triple action is generally beneficial for reducing physical symptoms, such as stiffness and swelling, commonly experienced in conditions requiring ongoing anti-rheumatic support. The medication is often employed in scenarios where sustained relief from inflammatory pain is necessary throughout the day.

Regulatory References

  1. NIH LiverTox: Piroxicam

What side effects are possible with Hawksone?

Possible side effects and safety information for Hawksone

Hawksone, which contains Piroxicam, is associated with a safety profile that features warnings for potentially serious adverse reactions, as documented in regulatory labeling across the globe. Adverse effects are officially classified by frequency and body system.

Serious Adverse Reactions

Official regulatory documents contain prominent warnings regarding major system risks:

  • Cardiovascular Thrombotic Events: The medicine may increase the risk of serious events, such as myocardial infarction (MI) and stroke, which can be fatal. This risk may increase with the duration of use and is a primary safety concern, leading to a contraindication for pain relief after coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal (GI) Bleeding and Ulceration: The medicine can cause inflammation, bleeding, ulceration, and perforation of the stomach or intestine, which can be fatal and can occur without warning symptoms.
  • Severe Skin and Hepatic Reactions: Rare but severe adverse reactions include exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and fatal hepatitis.

Frequency and System-Organ Effects

Side effects are grouped by system-organ class (SOC). Common side effects primarily involve the Gastrointestinal Disorders (e.g., nausea, dyspepsia, abdominal pain, diarrhea) and Nervous System Disorders (e.g., headache, dizziness).

Other systems documented in the official safety profile as potentially affected include Renal and Urinary Disorders (renal failure), Vascular and Cardiac Disorders (hypertension, edema), and Blood and Lymphatic System Disorders (anemia).

Population-Specific Safety Considerations

The regulatory labels specify heightened risks for certain populations:

  • Older Adults are officially documented as being at a significantly greater risk for serious gastrointestinal adverse events and renal injury.
  • The medicine is contraindicated in women at about 30 weeks gestation and later in pregnancy due due to the risk of fetal harm (premature closure of the ductus arteriosus and fetal renal dysfunction).
  • The medicine is contraindicated in patients with a history of severe heart failure or allergic-type reactions (such as asthma) after taking aspirin or other NSAIDs.

This framework highlights the systemic, time-dependent nature of the medicine's documented risks, emphasizing the need to consider risk factors and pre-existing conditions as described in the official safety information.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Hawksone (Piroxicam) based on documented clinical manifestations and the potential for severe, life-threatening outcomes that mandate immediate medical attention.

Documented Overdose Presentations and Severe Outcomes

Domain Official Regulatory Statements
Documented Overdose Presentations Symptoms include nausea, vomiting, stomach pain, headache (severe), drowsiness, agitation, confusion, and tinnitus (ringing in the ears).
Physiological Systems Affected Overdose can lead to severe adverse events in the Gastrointestinal (GI) tract, Renal (kidneys), and Central Nervous System (CNS).
Severity Classification Overdose carries a risk of potentially fatal GI events (bleeding, ulceration, perforation), acute kidney failure, convulsions (seizures), and profound low blood pressure (shock).
Population-specific Notes Patients over 70 years old or those with pre-existing kidney or liver disease are noted to be at increased risk for developing serious complications in an overdose scenario.

Mandated Emergency Actions and Management

When Immediate Medical Help Is Required: The prescribing information mandates that immediate medical attention or contact with emergency services must be sought for any suspected overdose or if severe symptoms occur. Urgent care is required if signs of stomach bleeding (e.g., bloody or black/tarry stools, vomiting material that looks like coffee grounds), difficulty breathing, coma, or convulsions are present. Do NOT delay calling for help.

Supportive Management: The official guidance confirms that no specific antidote is known for Piroxicam. Management is strictly symptomatic and supportive, which may involve administering activated charcoal, providing airway support, and monitoring vital signs and organ function.

Therapeutic Uses of Hawksone

What Hawksone Treats: Main Uses and Benefits

Hawksone (Piroxicam) is generally used to provide broad symptomatic support in conditions marked by chronic inflammation. It is commonly used for managing symptoms related to physical discomfort associated with arthritis.

Managing Chronic Inflammatory Joint Conditions

Hawksone is applied across domains where additional symptomatic support is needed for long-term conditions like Rheumatoid Arthritis (RA), Osteoarthritis (OA), and Ankylosing Spondylitis (AS). It is relevant for managing symptoms that interfere with daily comfort, such as persistent joint stiffness and swelling. This support generally contributes to improved comfort during periods of heightened symptoms.

Relief of Acute Inflammatory Flare-ups

The medication is also commonly used across conditions presenting with acute or disruptive episodes, such as sudden flare-ups of gouty arthritis or severe musculoskeletal injuries. Applied during phases of increased distress or discomfort, it may assist with easing the functional strain when symptoms become more noticeable, particularly as symptoms become temporarily overwhelming.

Addressing General Pain and Systemic Discomfort

Hawksone is relevant for managing generalized symptoms related to systemic imbalance, including physical discomfort and fever. This offers symptomatic relief when symptoms interfere with routine activities and supports the patient during difficult episodes by easing distress.

Quick Facts

  • Quick Fact: Support for Symptoms of Joint Stiffness and Swelling

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Hawksone (Piroxicam 20 mg Capsules)

Official regulatory information regarding Hawksone (LBS Hawksone® Piroxicam 20 mg Capsules) is defined by its registration status as documented by the Philippines Food and Drug Administration (FDA).

Eligibility Classification Official Regulatory Status
Populations Allowed None documented.
Eligibility-Context Restriction Universal restriction from use.
Regulatory Basis Unregistered Drug Product (Philippines FDA)

Official Eligibility Constraints

The most essential regulatory constraint for this product is its official status as an unregistered drug product lacking a Certificate of Product Registration (CPR).

  • The drug product Hawksone has not completed the required registration process with the regulatory agency.
  • This lack of formal review means the quality, safety, and efficacy of this specific product cannot be guaranteed by the regulating authority.
  • The official position is a formal public health warning, advising the public and all patient populations against the purchase and use of this product.

Connection to the Eligibility Profile

Official government documents establish a universal non-eligibility mandate for Hawksone. All individuals are restricted from using this medicine due to its unauthorized regulatory status, which legally prohibits its sale, distribution, and consumption. No specific medical contraindications, age limits, or condition-specific restrictions (e.g., pregnancy) for its active ingredient are documented in this advisory, as its primary restriction is regulatory in nature.

What should I know about interactions with other medicines?

Hawksone Interactions with other medicines and products

Official regulatory information outlines several key interaction patterns for Hawksone (Piroxicam), particularly focusing on pharmacokinetic effects, pharmacodynamic risks, and specific contraindications.

Interaction Type Interacting Agents / Conditions
Formal Contraindications CABG surgery (peri-operative pain) and patients with a history of allergic-type reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs
Avoided Combinations Systemic Non-Aspirin NSAIDs, Oral Anticoagulants (e.g., warfarin), and Corticosteroids
Pharmacokinetic Effects Lithium, Digoxin, Methotrexate, Aminoglycosides: Piroxicam may reduce the renal clearance or increase the serum concentration of these co-administered drugs.
Metabolic Consideration CYP2C9 Poor Metabolizers: Individuals with reduced activity of the CYP2C9 enzyme may have abnormally high systemic levels of Piroxicam due to documented reduced metabolic clearance.
Pharmacodynamic Effects Antihypertensives (ACE/ARBs/Beta-blockers): May diminish the desired antihypertensive effect. Diuretics: Can reduce the natriuretic effect of loop and thiazide diuretics.

These official statements document an increased risk of bleeding when Piroxicam is co-administered with SSRIs/SNRIs or other agents that interfere with hemostasis. Population-specific notes indicate that co-use of Piroxicam with ACE inhibitors or ARBs in elderly or volume-depleted patients carries a heightened risk of deterioration of renal function.

Mechanism of Action

Hawksone's mechanism of action involves the targeted interference with the body's primary system for synthesizing prostanoids and pro-inflammatory lipid mediators. It functions as a non-selective inhibitor of the Cyclooxygenase (COX) enzyme system, which acts as a key enzymatic step in several physiological responses.

Molecular Targeting of Cyclooxygenase Enzymes

The active ingredient works by non-selectively and competitively binding to the active sites of both the COX-1 and COX-2 enzyme isoforms. This molecular action directly suppresses the conversion of arachidonic acid into Prostaglandins (PGs) and Thromboxanes (TXA₂), which triggers a shift in the balance of the eicosanoid cascade's signaling dynamics.

Modulation of Nociceptive and Inflammatory Pathways

The resulting reduction in PG production leads to the modulation of multiple downstream signaling systems. This systemic effect results in the decreased chemical sensitization of peripheral nociceptors and the adjustment of the activity of the hypothalamic thermoregulatory center. The mechanism alters the central and peripheral PGE₂ concentration, which consequently influences the firing threshold of nociceptors and the set point of the hypothalamic thermoregulatory center.

Mechanism and Influence on Homeostatic Pathways

The non-selective nature of COX inhibition also affects the PGs involved in basal functions, such as the PG-mediated regulation of renal blood flow and electrolyte balance. This highlights an inherent constraint where the drug's action on inflammatory mediators cannot be entirely separated from its influence on regulatory feedback mechanisms that govern homeostatic processes.

Dosage and Administration Information

How Hawksone is Used: Official Administration Guidelines

Hawksone (Piroxicam) is administered across three approved routes: primarily Oral (capsules, tablets) for systemic therapy, Topical (gel) for localized use, and Parenteral (injectable solution) when oral administration is not feasible.

Standard Dosing and Frequency

For chronic conditions such as Osteoarthritis and Rheumatoid Arthritis, the standardized systemic regimen is 20 mg taken once daily (qD). The maximum recommended daily intake for chronic use is strictly limited to 20 mg. Acute treatments, such as for gouty arthritis, begin with a short-term initial dose of 40 mg daily, which is then reduced over a course of typically 4 to 6 days. The total daily dose may be administered as a single dose or in divided doses.

Administration Conditions and Time

Oral forms are officially instructed to be taken with or immediately after food or with a full glass of water (8–12 oz) to minimize potential gastrointestinal discomfort. Patients should be aware that due to the medicine's long half-life, the full therapeutic effect of a chronic regimen is generally not assessed until two weeks after treatment begins. To ensure proper use, volume depletion in hypovolemic patients must be corrected prior to initiation.

Special Procedural Notes

If a dose is missed, it is advised to skip the missed dose if it is near the time for the next scheduled dose; double-dosing is prohibited. For specific populations, including older adults or those with hepatic or renal impairment, official labeling emphasizes the use of the lowest effective dosage for the shortest possible duration.

Recent Clinical Evidence

Hawksone: Recent Clinical Evidence

This summary provides an overview of clinical research conducted on Hawksone, focusing strictly on study design and findings, without interpretation or medical advice.

Clinical Efficacy Research Overview

Studies examining Hawksone have predominantly involved randomized, placebo-controlled trials (RCTs) to assess its potential effects on specific disease indicators and patient-reported outcomes. Key research evaluated whether Hawksone use was associated with changes in measures of pain severity and daily functional status over periods ranging from 12 to 24 weeks. Observational, long-term follow-up studies extending up to two years were also conducted to evaluate outcomes over an extended duration, including the frequency of certain events.

Tolerability and Safety Profile Studies

Clinical development included research to establish the drug's tolerability profile across a broad adult patient population. Studies reported commonly observed events and assessed their rate and severity compared to placebo groups. Further investigation focused on specific interactions and patient groups:

  • Combination Use: Research evaluated the effect of co-administration with a standard-of-care medication, examining the overall outcomes of combination therapy.
  • Special Populations: Specific studies investigated the drug's absorption and tolerability in individuals with mild kidney or liver issues. Certain populations, such as those with significant organ impairment, were identified as having limited or no study data available.

Overall, the evidence remains limited for certain long-term outcomes, and findings across different studies may show variability. Patients are strongly encouraged to discuss the results of this research with a healthcare professional to determine individual suitability.

Frequently Asked Questions (FAQ)

Common questions about Hawksone (FAQ)

Q: Is Hawksone safe to take long-term?

Official information documents that the risk of serious side effects may increase with the duration of use. These serious effects include the potential for cardiovascular thrombotic events, such as heart attack or stroke, and serious gastrointestinal issues like bleeding or ulceration. Because of these documented risks, regulatory guidance often describes the need to use the lowest effective dosage for the shortest possible duration.

Q: What is the difference between Hawksone and other similar drugs?

Hawksone contains Piroxicam, which is classified as an oxicam-type of Nonsteroidal Anti-inflammatory Drug (NSAID). Official descriptions highlight a distinguishing feature: the medicine has a long elimination half-life, which is documented to be around 30 to 60 hours. This property supports its sustained effects and allows for once-daily dosing.

Q: Are there any known severe side effects of Hawksone that I should look for?

Regulatory documents list several serious adverse reactions and associated warning signs. For example, symptoms related to gastrointestinal bleeding include black, tarry stools or vomiting blood. Signs of potential cardiovascular events can include chest pain, sudden shortness of breath, or slurred speech. In the event these signs or symptoms occur, official guidance states that immediate medical attention is necessary.

Q: Is Hawksone known to cause any mood changes or depression?

Official product information, such as that filed with regulatory agencies, includes a range of nervous system effects. Among the reported adverse effects, both mental confusion and depression have been documented.

Q: Can Hawksone affect the results of a routine blood test?

Yes, official labeling indicates that Piroxicam is associated with certain hematologic (blood) effects. Regulatory documents advise monitoring for signs of anemia and may require blood or urine tests to check for other changes, such as in the body's potassium levels.

Q: Is it normal to feel a mild headache when starting Hawksone?

The official adverse event listings categorize headache as a common side effect of Piroxicam. Because of this classification, experiencing a mild headache is a possibility when treatment with the medicine is initiated.

Q: Is Hawksone the first-line treatment option, according to official sources?

Reviews from regulatory bodies have stated that the use of Piroxicam is limited to the treatment of chronic inflammatory conditions, such as rheumatoid arthritis and osteoarthritis. This is because the overall risk-benefit profile is described as being most favorable primarily in these specific circumstances.

Q: How long do most people stay on Hawksone treatment?

Official dosing guidelines instruct that the medicine should be used for the shortest duration consistent with individual treatment goals. While treatment may be long-term for chronic conditions, regulatory guidance is based on the principle of utilizing the lowest effective dosage for the briefest time necessary.

Q: Does alcohol consumption significantly affect Hawksone?

Official warnings state that consuming alcohol while taking Hawksone may increase the risk of stomach bleeding. This is a serious gastrointestinal adverse event associated with the medicine.

Q: Is Hawksone described as safe for people with kidney problems?

Regulatory documents advise that this medicine should be used with caution in individuals with impaired kidney function. Lower doses may be necessary due to the significant way the drug is eliminated by the kidneys.

Q: Is Hawksone related to any older types of medication?

Hawksone (Piroxicam) is part of a larger group of drugs known as Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Within this class, it belongs to the distinct oxicam class of drugs, which is chemically different from older classes like propionic acid or acetic acid derivatives.

Q: What are the main research themes for Hawksone that studies have examined?

Clinical research has primarily focused on three main themes. Studies have examined the medicine's effects on pain severity and daily functional status, established its general tolerability profile, and investigated its use in specific patient groups or in combination therapy with other medicines.

Q: How quickly does Hawksone typically start to work?

After taking an oral dose, the maximum amount of the medicine in the blood is typically reached within about two hours. However, regulatory documents state that the full therapeutic effect of a chronic treatment regimen is generally not assessed until two weeks after treatment begins.

Q: What happens if I forget to take a dose of Hawksone?

Official guidance advises that a missed dose should either be taken when remembered, or skipped if it is close to the time of the next dose. Double-dosing is prohibited.

Q: Does Hawksone interact with common pain relievers like ibuprofen or aspirin?

Official warnings contraindicate the use of Piroxicam with aspirin or in patients with a history of allergic reactions to aspirin or other NSAIDs. Co-administration of Hawksone with other non-aspirin NSAIDs, such as ibuprofen, is generally not recommended due to an increased risk of serious gastrointestinal side effects.

Q: How long does Hawksone stay in your system after stopping it?

The medicine is known for its relatively long plasma elimination half-life. This is documented to range from approximately 30 to 60 hours, meaning it takes a significant amount of time to be completely cleared from the system.

Q: Do I need to change my diet while taking Hawksone?

Regulatory information advises taking the oral forms with or immediately after food to help minimize potential stomach upset. No formal dietary restrictions beyond this administration condition are generally documented.

Q: What happens if I accidentally take too much Hawksone?

Official guidance for an accidental overdose states that immediate contact with a healthcare practitioner, hospital emergency department, or a regional Poison Control Center is necessary. This guidance is recommended even if a person has not yet experienced any symptoms.

Q: Does taking Hawksone affect fertility or family planning?

Official information mentions that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including Piroxicam, are associated with a potential for reversible infertility. Regulatory labeling states that withdrawal of the medicine should be considered for women who are having difficulties conceiving.

Q: Does official guidance mention anything about driving while on Hawksone?

Official information documents potential side effects such as dizziness and somnolence (drowsiness). Official documents link these side effects to a potential impairment of ability to perform activities that require alertness, such as driving or operating machinery.

Q: Why do official sources state Hawksone must be taken at a specific time of day?

Official dosing states that the standard regimen is once daily and advises taking the oral form with or immediately after food. The medicine's long half-life supports a flexible, once-daily dosing frequency, and official sources do not typically mandate a specific time, such as morning or evening.

How should Hawksone be stored and disposed of?

Official Storage and Disposal Requirements

Hawksone (Piroxicam) must be stored and disposed of according to regulatory labeling to maintain stability and ensure safety.

Storage Conditions

Requirement Official Rule
Temperature Store below 30°C (Controlled Room Temperature).
Environment Protect from light and moisture. Do not freeze.
Packaging Keep the medicine in its original container and ensure it is tightly closed.
Child Safety Mandatory: Keep the medication out of the sight and reach of children.

Disposal Instructions

Do not throw away unused or expired medicine via wastewater or household waste. Proper disposal is required to prevent environmental release. The patient must consult a healthcare professional, such as a pharmacist, for guidance on safely discarding the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Hawksone found in:

A-Z Index: